BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 2232168)

  • 1. [The expression of NCC-ST-439, a tumor marker, in human breast cancer patients].
    Miyahara E; Toi M; Wada T; Yamada H; Osaki A; Yanagawa E; Toge T
    Gan No Rinsho; 1990 Sep; 36(11):2023-6. PubMed ID: 2232168
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Study on the clinical usefulness of NCC-ST-439 in breast cancer].
    Takahashi H; Nakanishi K; Taguchi K; Hasumi T; Hamada H; Sasaki F; Hata Y; Uchino J
    Gan To Kagaku Ryoho; 1991 Feb; 18(2):245-9. PubMed ID: 1992918
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Clinical significance of serum NCC-ST 439 as a tumor marker for colorectal cancer].
    Yamaguchi A; Kurosaka Y; Ohta N; Kamata T; Ishida T; Nishimura G; Katoh M; Kosaka T; Yonemura Y; Miyazaki I
    Gan To Kagaku Ryoho; 1989 Aug; 16(8 Pt 1):2645-50. PubMed ID: 2549882
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Clinical significance of a tumor marker NCC-ST-439 in breast cancer--a comparative study with CA 15-3, CEA and TPA].
    Okamura Y; Takatsuka Y; Katoh T; Tsumura I; Kobayakawa K; Kawahara T
    Gan To Kagaku Ryoho; 1991 Jul; 18(8):1279-85. PubMed ID: 2069399
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Clinical evaluation of serum level of NCC-ST-439 as a new tumor marker for colorectal diseases--fluctuation of serum NCC-ST-439 in patients with colorectal cancers before and after surgery].
    Sakurai Y; Kodaira S; Teramoto T; Sugano K; Abe O; Ohtake H; Iri H
    Gan To Kagaku Ryoho; 1989 Sep; 16(9):3205-12. PubMed ID: 2782914
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Study on the clinical usefulness of NCC-ST-439 in cases of digestive tract cancer].
    Anzai K; Kurihara M; Izumi T
    Nihon Gan Chiryo Gakkai Shi; 1990 Jul; 25(7):1437-47. PubMed ID: 2212836
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Study on carbohydrate antigen NCC-ST-439 in breast cancer].
    Suzuki S; Nihei M; Nomizu T; Watanabe T; Kimijima I; Tsuchiya A; Abe R
    Nihon Gan Chiryo Gakkai Shi; 1990 May; 25(5):1019-26. PubMed ID: 2202768
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comparative analysis of the serum levels of NCC-ST-439, CEA and CA19-9 in patients with colorectal carcinoma.
    Iemura K; Moriya Y
    Eur J Surg Oncol; 1993 Oct; 19(5):439-42. PubMed ID: 8405479
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Clinical evaluation of a combination assay of CEA, CA-19-9 and TPA in patients with colorectal cancer].
    Nishida O; Shiroto H; Satoh N; Nakajima Y; Manabe K; Kondoh Y; Sano F; Uchino J
    Gan No Rinsho; 1988 Aug; 34(9):1096-100. PubMed ID: 3172515
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [CA 15-3 and CEA as tumor markers in the diagnosis of the recurrence of breast cancer].
    Engel K; Schmid H; Hanke J; Kaufmann M; Müller A
    Geburtshilfe Frauenheilkd; 1988 May; 48(5):309-12. PubMed ID: 3165077
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Clinical usefulness of tumor markers in breast cancer].
    Konishi K; Karaki K; Watanabe K; Tsuda H; Konishi F
    Rinsho Byori; 1993 Oct; 41(10):1108-15. PubMed ID: 8254956
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Study for clinical usefulness of CEA, TPA, CA15-3 and BCA225 in breast cancer].
    Kaneko Y; Imoto S; Kasakura S
    Rinsho Byori; 1995 Jul; 43(7):696-702. PubMed ID: 7674542
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Clinical evaluation of a new tumor marker, CA 15-3, in breast cancer; a comparative study with CEA].
    Komuro K; Watanabe K; Ishida T; Sakurai M; Amano R; Hagiwara H; Hara Y; Hanzawa T; Itsubo K
    Gan To Kagaku Ryoho; 1986 Oct; 13(11):3145-9. PubMed ID: 3465273
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Clinical study of the NCC-ST-439 EIA kit using serum from patients with various types of cancer and benign disease (2)].
    Ohkura H; Hattori N; Miyazaki I; Sawabu N; Tobe R; Kawai K; Abe O; Ishii M; Kawai T; Kamano T
    Gan To Kagaku Ryoho; 1987 Jun; 14(6 Pt 1):1907-12. PubMed ID: 2439021
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical evaluation of new serum tumor markers CA M26 and CA M29 in patients with primary breast cancer.
    Eskelinen M; Tikanoja S; Brown J
    Anticancer Res; 1990; 10(4):959-62. PubMed ID: 2382995
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early diagnosis of breast cancer dissemination by tumor markers follow-up and method of prediction.
    Nekulová M; Simícková M; Pecen L; Eben K; Vermousek I; Stratil P; Cernoch M; Lang B
    Neoplasma; 1994; 41(2):113-8. PubMed ID: 8208314
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Estimates of circulating breast cancer-associated antigen CA 15-3 as a monitoring marker in patients with breast cancer].
    Yoshimoto M; Akiyama F; Watanabe S; Kasumi F; Fukami A; Nakajima T; Nishi M; Kajitani T; Takahashi S
    Gan To Kagaku Ryoho; 1987 Jul; 14(7):2310-5. PubMed ID: 3475042
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined measurement of serum sialyl Lewis X with serum CA15-3 in breast cancer patients.
    Kurebayashi J; Nomura T; Hirono M; Okubo S; Udagawa K; Shiiki S; Ikeda M; Nakashima K; Tanaka K; Sonoo H
    Jpn J Clin Oncol; 2006 Mar; 36(3):150-3. PubMed ID: 16520359
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Tumor marker: practical usage of tumor marker for recurrent breast cancer--our experience].
    Yoshimoto M
    Gan To Kagaku Ryoho; 1990 Nov; 17(11):2277-83. PubMed ID: 2241194
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cancer-associated antigen CA 15-3 in the diagnostics of breast tumours.
    Eskelinen M; Tikanoja S; Valkamo E; Loikkanen M; Collan Y
    Scand J Clin Lab Invest; 1988 Nov; 48(7):653-8. PubMed ID: 3201097
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.